Accession Number: | 0000886163-21-000093 |
Date: | 2021-06-04 |
Issuer: | LIGAND PHARMACEUTICALS INC (LGND) |
Original Submission Date: |
BOYCE SARAH
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-06-04 | A | 630 | a | $0.00 | 2,892 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) | 115.39 | 2021-06-04 | deemed execution date | A | 3,269 (a) | 2031-06-04 | common stock 3,269 | $115.39 | 3,269 | direct |
ID | footnote |
---|---|
f1 | acquired by a grant of the board of directors of the company at their annual meeting on june 04, 2021. fully vests on the earlier of (a) the date of the next annual meeting of the company stockholders following the grant date or (b) on the first anniversary of the date of grant. |
f2 | acquired by a grant of the board of directors of the company at their annual meeting on june 04, 2021. fully vests on the earlier of (a) the date of the next annual meeting of the company stockholders following the grant date or (b) on the first anniversary of the date of grant. |